Private equity investor with a background in Science/Bio-technology for asset managers. MBA from Duke and PhD from The University of British Columbia (UBC).
Qing Peng is a private equity investor with 18.3 years of experience in the field. He has expertise in HPLC, biochemistry, molecular biology, and protein purification. Qing has worked at J.P. Morgan in the United States and China eCapital Corporation in China, holding positions such as Vice President and Senior Associate. He also has experience as a Sr. Investment Manager and Senior Researcher. Qing is skilled in various areas including organic synthesis, cell culture, and spectroscopy. He is currently based in Hong Kong.
Cec Capital Group is a leading private investment bank in China. Founded in 2000, we have serviced more clients and transactions than any other investment banking boutique in China. We provide advisory services in Mergers & Acquisitions (M&A), Private Placements, and Initial Public Offerings (IPO). While our clients encompass a wide spectrum of industries, over the years we have developed core competencies and strong vertical expertise in the following sectors: i ) technology, media and entertainment, ii ) health care and life sciences, iii ) consumer products and services, and iv ) cleantech.
Raleigh,North Carolina,United States
Founded by a team of accomplished industry professionals who began working together in 2000, NovaQuest Capital Management is a premier biopharma and life sciences investment firm. NovaQuest pioneered a Product Finance solution for the industry, providing at-risk, nondilutive funding that enables partner companies to advance pivotal clinical trials, launch new brands, license products, and acquire accretive products or companies. NovaQuest has invested in scores of biopharmaceutical assets across therapeutic areas with a clinical success rate significantly higher than the industry average. Currently managing more than $2.2 billion in capital, NovaQuest is actively investing from the $1.2 billion Pharma Opportunities Fund V, evaluating global opportunities with financing needs that range from $30-100 million. For more information, please visit www.novaquest.com
Acidophil is an innovation company that uses technical and business information together with bio-chemical capabilities to create, manage and co-finance new products and biotechnology businesses in human health, agriculture, and animal health. With operations in both the United States (Lutherville, MD) and United Kingdom (Cambridge), Acidophil takes a global approach to innovation, management and investment that reflects the international perspective of its team and founders. Acidophil exploits a virtual business development model to enable capital efficient innovation in collaboration with scientists, entrepreneurs, corporations and investors who are interested in addressing global market needs.
For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of disease, and giving back to communities through philanthropy and volunteerism. General Information and Guidelines: Eli Lilly and Company strives to create informative and engaging online communities that share information in meaningful ways. We welcome and encourage your participation and engagement in thoughtful and respectful discourse. When you engage with Lilly on LinkedIn (and any other of Lilly’s social media channels), you are agreeing to these Community Guidelines in addition to the Terms and Conditions or other legal notices provided by Lilly and those of LinkedIn: https://e.lilly/guidelines If you have any questions about a Lilly therapy or medicine, please contact our customer care line at 1-800-LillyRx (1-800-545-5979) Monday through Friday in the U.S., excluding holidays.
Durham,North Carolina,United States
For nearly a century, we have delivered on our commitment to saving and sustaining the lives of patients, working alongside clinicians and providers around the world. We believe every person — regardless of who they are or where they are from — deserves a chance to live a healthy life, free from illness and full of possibility. At the intersection of progress and purpose is where we are redefining what it means to be a global medtech leader. It is where we are relentlessly pursuing healthcare transformation, fueled by our compassion for patients and providers and the challenges they face. It is where bold ideas meet the promise for meaningful change in the world around us. We are there, at every step of the journey, to help clinicians deliver the best care possible.
City of Hope's mission is to deliver the cures of tomorrow to the people who need them today. Founded in 1913, City of Hope has grown into one of the largest cancer research and treatment organizations in the U.S. And one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines, as well as human synthetic insulin and monoclonal antibodies. With an independent, National Cancer Institute-designated comprehensive cancer center at its core, City of Hope brings a uniquely integrated model to patients spanning cancer care, research and development, academics and training, and innovation initiatives. City of Hope’s growing national system includes its Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California, and treatment facilities in Atlanta, Chicago and Phoenix. City of Hope’s affiliated group of organizations includes Translational Genomics Research Institute and AccessHope™.
High Performance Liquid Chromatography
Single Molecule Mechanics
We found 2 Qing Peng's email addresses
We found 1 Qing Peng's phone numbers
Qing Peng works for J.P. Morgan
Qing Peng's role in J.P. Morgan is Vice President
Qing Peng works in the industry of
Qing Peng's colleagues are
Qing Peng's latest job experience is Vice President at J.P. Morgan
Qing Peng's latest education in The University of British Columbia